Podder I, Das A, Ghosh S, et al. - Researchers conducted the study for comparing the efficacy, safety, and tolerability of bilastine, a novel H1 antihistamine, 20 mg vs levocetirizine 5 mg in moderate‐to‐severe chronic spontaneous urticaria (CSU). They performed a double‐blind, randomized controlled trial with two groups: bilastine 20 mg (n = 31) and levocetirizine 5 mg (n = 27), once daily for 42 days. Patients, aged 18 to 65 years, with moderate‐to‐severe CSU were included. UAS7, VAS, and DLQI have been used to determine the severity of urticaria, global urticaria‐induced discomfort, and quality of life, respectively. DLQI was evaluated at baseline (D0) and end‐of‐treatment (D42), whereas UAS7 and VAS were noted at baseline and all follow‐up visits. UAS7 and VAS improved significantly D14 onwards in both the groups and were maintained throughout the investigation. Sedation with bilastine was significantly less, although neither drug had any serious adverse effect. Both medications had equal tolerability. Bilastine has also been found to be a more effective and less sedative novel therapy for CSU than levocetirizine, with comparable effects on quality of life.